Aprea Therapeutics Will Present APR-1051 Trial Results
The precision oncology company will share Phase 1 data during an oral presentation in Barcelona this November.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies are transparent when reporting results from experimental cancer drug trials?
Aprea Therapeutics will present updated interim results from its Phase 1 clinical trial of the WEE1 inhibitor APR-1051 on November 20, 2026. The presentation will take place during the 38th EORTC-NCI-AACR Symposium in Barcelona, Spain.
Why it matters
The findings provide new data on the efficacy and safety of APR-1051 in treating patients with advanced solid tumors, a key focus for the clinical-stage biotech company. This update offers a clearer look at the development of precision WEE1 inhibition therapies.
The study, identified as ACESOT-1051, is testing the WEE1 inhibitor APR-1051 in a Phase 1 clinical trial. These results are being presented as part of the 38th edition of the EORTC-NCI-AACR Symposium.
The players
Aprea Therapeutics
Aprea Therapeutics is a clinical-stage precision oncology company based in Doylestown, Pennsylvania.
Timothy A. Yap
Timothy A. Yap is the researcher scheduled to present the updated clinical trial findings on behalf of the company.
The details
Timothy A. Yap is scheduled to deliver an oral plenary presentation regarding the clinical trial findings. The report will detail the ongoing assessment of APR-1051, which is designed as a precision oncology treatment for patients facing advanced solid tumors.
Timeline
November 18-20, 2026: The 38th EORTC-NCI-AACR Symposium takes place.
November 20, 2026: Timothy A. Yap will present the trial findings.
November 20, 2026, 3 p.m. to 3:10 p.m. CET: The specific time slot for the oral presentation.
The Big Picture
This presentation is scheduled for the EORTC-NCI-AACR Symposium, which serves as a major platform for disseminating initial clinical data for oncology drugs. The upcoming presentation follows the symposiums long-standing pattern of hosting high-level updates on emerging cancer therapies.
While the trial remains in the Phase 1 stage, the data being presented provides insight into the potential future availability of new WEE1 inhibitor treatments. Patients should consult with their oncologists to understand how such research developments may eventually impact standard care protocols.
The takeaway
The upcoming symposium presentation serves as a critical milestone for Aprea Therapeutics to share progress in their precision oncology pipeline. Investors and medical professionals will be looking for early safety and efficacy signals from the ACESOT-1051 trial.
Further reading
For more on the current landscape of oncology research, visit the Cancer section.
More information
You can view the official details of the study on the ClinicalTrials.gov trial information page.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you trust that pharmaceutical companies are transparent when reporting results from experimental cancer drug trials?
